Dear Colleague, Dear all,
We are pleased to report that the ESCMID PK/PD of Anti-Infectives Study Group (EPASG, www.escmid.org/epasg) is about to complete its founding and first year with a number of significant accomplishments. As well, heightened recognition of the importance of evidence- based dosing decisions in optimizsing drug activity while minimising resistance development has resulted in a steady increase of interest in the field of PK/PD. Combined with this increased interest, our efforts and results have captured the attention of the more than 330 members from 68 countries who have joined EPASG in our first year alone.
Indeed, EPASG's first year has seen numerous accomplishments from our active members: Ursula Theuretzbacher, Johan Mouton, Franšoise Van Bambeke, Otto Cars, Nils Frim°dt-M°ller, Alasdair MacGowan, William Couet, Yehuda Carmeli, Mical Paul, Lena Friberg, Klaus Skovbo Jensen, Andrew Lovering, Paul Tulkens, Antonios Markogiannakis, Dimitrios. Matthaiou, Joseph Meletiadis, Maria-Jose GimÚnez, Ingrid Nilsson, Inga Odenholt, Jordi Rello, and Lorenzo Aguilar.
Members of EPASG carefully prepared and submitted an application for a two-stage grant: FP7-HEALTH.2011.2.3.1-1 investigator-driven clinical trials of off-patent antibiotics, which has just been accepted by the European Commission.
EPASG Workshop chaired by Johan Mouton at the conference "Global Need for Effective Antibiotics-Moving towards Concerted Action", Uppsala, SE, 6 - 8 September 2010. The resulting publication "Conserving antibiotics for the future - New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective" has been published in the journal "Drug Resistance Updates" with action recommendations.
Contributions to policy issues discussion
Comments on EMA’s draft guideline, Guideline on the Evaluation of Medicinal Products indicated for Treatment of Bacterial Infections.
Submission of several articles to relevant high impact journals. Of particular note is a consensus paper reviewing in vitro testing of the impact of protein binding on antibacterial activity that will shortly appear in Antimicrobial Agents and Chemotherapy.
A regularly updated report of EPASG activities and accomplishments can be found on our website.
As you can see, our first year was a successful jump start that initiated Europe-wide programmes with a focus on PK/PD of anti-infectives. Everyone who is interested in using anti-infectives in an optimal way is encouraged to join in our vision to improve patient care.
To stay informed about our activities and the PK/PD field log in or register at the ESCMID website, go to “My profile” and tick the box for EPASG (second page of profile).
We are inviting all who are interested in our activities to join us for the EPASG business meeting during the ECCMID/ICC 2011. It will take place on 8 May, 12:30 – 13:30 in the Press Conference Room. We plan to discuss next year’s activities and hope to receive as much input as possible. Please plan to attend, enrich the pool of ideas, and participate in our educational and research activities!
To participate in our activities, please contact us directly: Johan Mouton
We appreciate any comments, suggestions, and contributions!
Ursula Theuretzbacher (Chairperson) Johan Mouton (Secretary) Franšoise Van Bambeke (Treasurer)
The e-mail is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.
You can unsubscribe by answering this email and including the word 'unsubscribe' in the subject line.